Eli Lilly Acquires FXR 314 Program
Organovo Holdings, Inc. a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) announced that Eli Lilly and Company will acquire Organovo’s FXR program, including its lead asset, FXR 314
“This is a significant milestone for our efforts to advance medicines for IBD using insights from our proprietary 3D human tissue models,” said Keith Murphy, Executive Chairman. “We are excited to deliver FXR 314 and our FXR program to Lilly for PhaseII2 and further development. Their world-class development excellence and dedication to delivering for patients will provide an excellent pathway for FXR 314 success, and we are pleased to have this opportunity to deliver for patients.”
Under this transaction, Organovo will receive an upfront payment as well as milestones to be paid as FXR 314 achieves key regulatory and commercial milestones. Lilly is acquiring all commercial and intellectual property rights to Organovo’s FXR program for worldwide development.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.